EGFR

(redirected from ErbB)
Also found in: Acronyms, Wikipedia.

EGFR

EGFR

A gene on chromosome 7p12 that encodes epidermal growth factor, a transmembrane glycoprotein of the protein kinase superfamily, which is a receptor for members of the epidermal growth factor family. Binding of the protein to a ligand induces receptor dimerisation and tyrosine autophosphorylation and leads to cell proliferation.

Molecular pathology
EGFR mutations are associated with lung cancer.

EGFR

Abbreviation for epidermal growth factor receptor.

eGFR

estimated glomerular filtration rate.
References in periodicals archive ?
ERBB signaling was reported as a major steroid-independent activator of AR.
In the new study, Lauffenburger and colleagues set out to identify factors that help tumor cells become resistant to EGFR and other ErbB inhibitors.
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
As noted above, EGFR is a member of the erbB family of receptor tyrosine kinase proteins, now known to also include HER2/neu (erbB2), HER3 (erbB3), and HER4 (erbB4).
EGFR (also called erbB1) is the first member of a closely related group of tyrosine kinase receptors known as the erbB family, the remaining three being erbB2, erbB3 and erbB4.
Experimental studies have shown that alternative erbB receptor (HER1, HER3, HER4) heterodimerisation and subsequent mitogenic signalling may be present de novo, or be acquired during trastuzumab treatment, in HER2-positive breast cancer cell tumours.
com/quote/ERBB:US) ERBB became one of the first publicly-traded technology companies in the world to address the burgeoning medical and now, legal adult-use cannabis industry.
The Tranzbyte division of American Green will continues its plan to acquire, hold, or spin out successful divisions in what has been described as "dividend farming," Companies that qualify and decide to become public will agree to carve out shares for the company and dividends for their ERBB shareholders.
Data support advancing NT-113 into clinical development for the treatment of erbB positive GBM, including patients with the disease driving EGFRvIII mutation.
The company s oncology portfolio includes Giotri (afatinib), an irreversible ErbB family blocker, approved in a number of markets, including the EU, the US and Japan for the treatment of distinct types of EGFR mutation-positive NSCLC.
As part of a collaboration with Boehringer Ingelheim, Beactica scientists provided important insights into the interactions between afatinib (BIBW 2992) and members of the ErbB receptor family.
The neu oncogene: an erbB related gene encoding a 185,000-Mr turnout antigen.